Tempus AI (TEM) said Monday it completed purchase of Ambry Genetics for $600 million, including $375 million in cash and $225 million in shares.

Of the stock portion of the purchase tag, $100 million is under a lock-up agreement, restricting their sale for one year after the deal closed, the company said.

Ares Management Credit provided financing for the acquisition, it added.

Ambry Genetics will operate as a wholly-owned subsidiary of Tempus, retaining its leadership team, according to the company.

Tempus shares were up over 3% in recent after-market activity.